Clinical Trials Browser

Phase 2 × Glioblastoma × osimertinib × Clear all

NCT03732352 2024-11-12

18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma

Phase 2 Completed

Glioblastoma